Profile data is unavailable for this security.
About the company
Beijing Tiantan Biological Products Corp Ltd is a China-based company principally engaged in the research and development, production and sales of blood products. The Company's main products include human albumin, human immunoglobulin (pH4) for intravenous injection, human immunoglobulin, human rabies immunoglobulin, human hepatitis B immunoglobulin, human histamine immunoglobulin, human prothrombin complex and others. The Company's products are mainly used to treat shock caused by blood loss, trauma and burns, treat primary immunoglobulin G deficiency, neonatal sepsis, infant bronchiolitis, prevent and treat tetanus and others. The Company mainly operates its businesses in the domestic and overseas markets.
- Revenue in CNY (TTM)6.42bn
- Net income in CNY1.32bn
- Incorporated1998
- Employees5.30k
- LocationBeijing Tiantan Biological Products Corp LtdNo. 2Shuangqiao Road B, Chaoyang DistrictBEIJING 100024ChinaCHN
- Phone+86 1 065439720
- Fax+86 1 065436770
- Websitehttps://www.tiantanbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kangmei Pharmaceutical Co Ltd | 5.28bn | 16.64m | 26.69bn | 4.23k | 1,678.26 | 3.71 | -- | 5.06 | 0.0012 | 0.0012 | 0.3973 | 0.5197 | 0.3785 | 1.64 | 2.23 | 1,246,204.00 | 0.1368 | -21.82 | 0.2232 | -42.17 | 17.12 | -92.73 | 0.3614 | -108.18 | 0.7875 | -- | 0.0162 | -- | 6.47 | -14.63 | -91.64 | -- | -33.46 | -- |
| Xiamen Amoytop Biotech Co Ltd | 3.34bn | 939.58m | 28.11bn | 2.42k | 29.81 | 9.31 | -- | 8.41 | 2.31 | 2.31 | 8.22 | 7.40 | 1.03 | 0.8127 | 4.99 | 1,379,284.00 | 29.05 | 22.72 | 33.93 | 26.54 | 92.37 | 91.62 | 28.11 | 23.51 | 3.20 | -- | 0.0448 | 28.80 | 34.13 | 31.02 | 49.00 | 66.70 | 41.17 | 90.06 |
| Bluestar Adisseo Co | 17.09bn | 1.19bn | 30.80bn | 2.93k | 22.49 | 1.59 | -- | 1.80 | 0.4447 | 0.4447 | 6.37 | 6.31 | 0.7204 | 5.30 | 8.18 | 5,834,541.00 | 5.03 | 5.20 | 6.05 | 6.63 | 27.69 | 29.69 | 6.99 | 8.12 | 1.12 | 10.31 | 0.1377 | 30.01 | 17.83 | 6.88 | 2,208.66 | 3.95 | 5.53 | -7.02 |
| Humanwell Healthcare Group Co Ltd | 24.18bn | 1.43bn | 30.87bn | 17.65k | 21.63 | 1.63 | -- | 1.28 | 0.8741 | 0.8741 | 14.84 | 11.59 | 0.6519 | 3.63 | 2.48 | 1,369,715.00 | 5.00 | 6.40 | 8.73 | 12.55 | 44.53 | 43.83 | 7.67 | 9.90 | 1.40 | 362.14 | 0.2889 | 25.97 | 3.71 | 3.13 | -37.70 | 11.15 | 4.75 | 56.54 |
| Tianjin Pharmcetl Da Ren Tang Grp Cp Ltd | 5.37bn | 3.58bn | 31.26bn | 3.84k | 10.03 | 3.99 | -- | 5.83 | 4.65 | 4.65 | 6.98 | 11.70 | 0.4758 | 1.35 | 3.16 | 1,399,130.00 | 31.64 | 11.74 | 45.06 | 16.76 | 64.27 | 42.04 | 66.50 | 14.81 | 2.33 | -- | 0.0056 | 54.04 | -11.14 | 0.8791 | 125.94 | 28.94 | -10.54 | 33.67 |
| Shanghai Junshi Biosciences Co Ltd | 2.48bn | -949.86m | 32.48bn | 2.67k | -- | 5.90 | -- | 13.08 | -0.96 | -0.96 | 2.51 | 6.05 | 0.2203 | 0.8436 | 5.48 | 963,148.80 | -9.45 | -17.61 | -12.31 | -22.00 | 81.59 | 68.46 | -42.92 | -84.56 | 1.43 | -23.04 | 0.3629 | -- | 29.67 | 20.24 | 43.90 | -- | -4.33 | -- |
| Beijing Tiantan Biological Products Corp | 6.42bn | 1.32bn | 32.63bn | 5.30k | 24.79 | 2.85 | -- | 5.08 | 0.6656 | 0.6656 | 3.25 | 5.80 | 0.4002 | 0.9382 | 11.21 | 1,212,453.00 | 11.25 | 11.93 | 16.06 | 16.79 | 45.65 | 50.69 | 28.10 | 29.69 | 3.08 | -- | 0.0152 | 16.24 | 16.44 | 12.94 | 39.58 | 20.45 | 15.19 | 23.56 |
| Sunshine Guojian Pharmcutcl Shngh Co Ltd | 1.37bn | 870.39m | 37.38bn | 995.00 | 43.14 | 6.32 | -- | 27.28 | 1.40 | 1.40 | 2.21 | 9.56 | 0.186 | 1.54 | 4.55 | 1,377,045.00 | 11.66 | 3.14 | 15.35 | 3.34 | 74.88 | 77.37 | 62.65 | 16.95 | 1.97 | -- | 0.00 | 12.57 | 17.70 | 0.2733 | 139.15 | 25.17 | 16.61 | -- |
| Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd | 77.54bn | 2.99bn | 39.60bn | 28.14k | 13.88 | 1.09 | -- | 0.5107 | 1.84 | 1.84 | 47.69 | 23.32 | 0.9548 | 5.79 | 4.33 | 2,755,662.00 | 3.83 | 5.33 | 7.36 | 10.95 | 16.23 | 18.07 | 4.01 | 5.28 | 1.31 | -- | 0.2873 | 28.87 | -0.692 | 2.92 | -30.09 | -2.32 | -14.01 | 6.32 |
Data as of Feb 11 2026. Currency figures normalised to Beijing Tiantan Biological Products Corp Ltd's reporting currency: Chinese Yuan Renminbi CNY
7.15%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| E Fund Management Co., Ltd.as of 30 Jun 2025 | 43.55m | 2.20% |
| Huatai-PineBridge Fund Management Co., Ltd.as of 30 Jun 2025 | 22.84m | 1.16% |
| China Merchants Fund Management Co., Ltd.as of 30 Jun 2025 | 17.93m | 0.91% |
| China Asset Management Co., Ltd.as of 30 Jun 2025 | 13.19m | 0.67% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 10.45m | 0.53% |
| Tian Hong Asset Management Co., Ltd.as of 30 Jun 2025 | 7.94m | 0.40% |
| Guotai Asset Management Co., Ltd.as of 30 Jun 2025 | 7.55m | 0.38% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 6.61m | 0.33% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 6.21m | 0.31% |
| The Vanguard Group, Inc.as of 07 Jan 2026 | 5.08m | 0.26% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
